Spark Therapeutics (ONCE) Misses Q2 EPS by 66c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Spark Therapeutics (ONCE) PT Raised to $92 at Stifel
August 2, 2017 1:19 PM EDTStifel analyst Stephen Willey raised his price target on Spark Therapeutics (NASDAQ: ONCE) to $92.00 (from $77.00) while maintaining a Buy rating following positive P1/2 SPK-8011 data in hemophilia A.
Willey commented, "We believe this data (while understandably limited in scope/scale) establishes proof-of-concept, suggests... More
Spark Therapeutics (ONCE) PT Raised to $95 at Cowen
August 2, 2017 1:09 PM EDTCowen analyst Phil Nadeau raised his price target on Spark Therapeutics (NASDAQ: ONCE) to $95.00 (from $75.00) while maintaining an Outperform rating after SPK-8011 produced encouraging early data in 3 Hem A patients, with a low 5e11 dose producing average FVIII levels of 12% in 2 patients, and with... More
Spark Therapeutics (ONCE) PT Raised to $95 at Jefferies
August 2, 2017 12:29 PM EDTJefferies analyst Michael Yee raised his price target on Spark Therapeutics (NASDAQ: ONCE) to $95.00 (from $85.00) while maintaining a Buy rating.
... More